Trial Profile
A Multicenter, Masked, Randomized, Sham-Controlled, Parallel-Group, 3 Month Study with a 9-Month Safety Extension to Evaluate the Safety and Efficacy of Brimonidine Tartrate Posterior Segment Drug Delivery System (Brimonidine Tartrate PS DDS®) Applicator System in Improving Visual Function in Patients with a Previous Rhegmatogenous Macula-Off Retinal Detachment
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Aug 2016
Price :
$35
*
At a glance
- Drugs Brimonidine (Primary)
- Indications Retinal detachment
- Focus Therapeutic Use
- Sponsors Allergan
- 05 Apr 2014 New trial record
- 18 Oct 2011
- 16 Sep 2010